<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550432</url>
  </required_header>
  <id_info>
    <org_study_id>SU-03252010-5442</org_study_id>
    <secondary_id>R21AT004475</secondary_id>
    <nct_id>NCT01550432</nct_id>
  </id_info>
  <brief_title>Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation</brief_title>
  <official_title>Effects of GSH and N-Acetylcysteine on Inflammatory Markers Among Adults With CVD Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale for the potential role of antioxidants in the prevention of cardiovascular
      diseases (CVD) remains strong despite the disappointing results of recent trials with a few
      select antioxidant vitamins. Glutathione (GSH) is one of the body's most powerful antioxidant
      agents but there is a surprising paucity of data on its use as an interventional therapy.

      Glutathione, when taken orally, is immediately broken down into its constituent amino acids,
      of which cysteine is the only one to be essential. Available cysteine is the critical
      determinant of intracellular GSH concentrations. N-acetyl cysteine (NAC) is an antioxidant
      supplement that has been used to provide a source of cysteine to replete GSH levels. By
      replenishing endogenous glutathione, it is possible that NAC would exert the same effect(s)
      as exogenous GSH.

      However, there is a new delivery system, liposomal GSH, which keeps glutathione intact. In
      this study, the investigators propose to match the cysteine content of NAC and GSH and
      compare the effects of these two supplements, at two different doses, on markers of
      inflammation and oxidative stress.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory Markers</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxidized LDL</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum lipids</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glutathione levels</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Obesity</condition>
  <condition>Hyperlipidemia</condition>
  <condition>Insulin Resistance</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>High-Dose Glutathione</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2,260 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose Glutathione</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,130 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Dose N-Acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,200 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-Dose N-Acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Volume of liquid placebo product comparable to glutathione and 1 or 2 placebo pills/day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glutathione</intervention_name>
    <description>1,130 mg/day or 2,260 mg/day for 8 weeks</description>
    <arm_group_label>High-Dose Glutathione</arm_group_label>
    <arm_group_label>Low-Dose Glutathione</arm_group_label>
    <other_name>ReadiSorb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>600 mg/day or 1,200 mg/day for 8 weeks</description>
    <arm_group_label>High-Dose N-Acetylcysteine</arm_group_label>
    <arm_group_label>Low-Dose N-Acetylcysteine</arm_group_label>
    <other_name>Twinlab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Volume of liquid placebo product comparable to liposomal glutathione and 1 or 2 placebo pills/day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Nutrilite</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Gender: Both women and men

          2. Age: &gt; or = 18 years

          3. Ethnicity and race: All ethnic and racial backgrounds welcome

          4. Presence of Metabolic Syndrome: As defined in ATP III of the National 5.Cholesterol
             Education program, the metabolic syndrome will be diagnosed as presence of at least
             three of the following, which will be measured at the screening clinic visit:

               -  Central obesity as measured by waist circumference:

                    -  Men: Greater than 40 inches

                    -  Women: Greater than 35 inches

               -  Fasting blood triglycerides greater than or equal to 150 mg/dL

               -  Blood HDL cholesterol:

                    -  Men: Less than 40 mg/dL

                    -  Women: Less than 50 mg/dL

               -  Blood pressure greater than or equal to 130/85 mmHg

               -  Fasting glucose greater than or equal to 100 mg/dL

        6.Planning to be available for clinic visits and bottle pick-ups for the 8 weeks of study
        participation 7.Ability and willingness to give written informed consent 8.No known active
        psychiatric illness.

        Exclusion Criteria:

          1. Daily intake of dietary supplements containing antioxidants or omega-3 FAs

          2. Fasting blood glucose &gt; 140 mg/dL

          3. Significant liver enzyme abnormality

               -  AST or ALT more than 2 times the upper limit of normal and/or

               -  Bilirubin more than 50% the upper limit of normal

               -  Renal disease as measured at baseline:

               -  Serum creatinine &gt; 1.30 mg/dL, or

               -  Calculated creatinine clearance &lt; 71 mL/min

          4. Self reported personal history of:

               -  Clotting disorders

               -  Clinically significant atherosclerosis (e.g., CAD, PAD)

               -  Malignant neoplasm

               -  Ongoing infection

               -  Inflammatory disease (e.g., rheumatoid arthritis)

          5. Subjects currently receiving the following medications (self report):

               -  Anti-Inflammatory drugs

               -  Lipid lowering drugs including statins

               -  Anti-hypertensive drugs

               -  Anti-coagulant drugs

          6. Body Mass Index (BMI) greater than or equal to 40.

          7. Pregnant or Lactating

          8. Inability to communicate effectively with study personnel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher D Gardner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://med.stanford.edu/nutrition/nutrition-studies-group/completed-studies/antioxidants-and-cvd.html</url>
    <description>Study description and on-line screening survey</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2011</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Christopher Gardner</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

